Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Relationship between vaccination dose and the cumulative incidence rate of adverse events associated with pentavalent vaccine in children

From: Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran

Adverse events Incidence (per 100 children) RRa (95% CI)
First dose
N = 373
Second dose
N = 372
Third dose
N = 374
Swelling 79(44.6) 50(28.2) 48(27.1) 0.72(0.59–0.89)
Redness 50(40.7) 30(24.4) 43(35) 0.9(0.72–1.14)
Pain 190(38.4) 143(28.9) 162(32.7) 0.85(0.74–0.99)
Mild fever 45(31.9) 33(23.4) 63(44.7) 1.24(1.00–1.54)
High fever 1(100) 0(0) 0(0) NA
Drowsiness 83(36.9) 72(32) 70(31.1) 0.89(0.74–1.07)
Anorexia 65(38.7) 51(30.4) 52(31) 0.87(0.71–1.06)
Restlessness 135(36.6) 115(31.2) 119(32.2) 0.9(0.77–1.05)
Vomiting 16(30.8) 19(36.5) 17(32.7) 1.02(0.73–1.44)
Long-term crying 24(38.7) 16(25.8) 22(35.5) 0.94(0.69–1.29)
Encephalopathy 0(0) 0(0) 0(0) Not applicable
Convulsion 0(0) 0(0) 0(0) Not applicable
History of convulsion 0(0) 1(0.2) 2(0.5) 3.45(0.5–23.74)
Family history of convulsion 0(0) 14(3.7) 6(1.6) 1.6(0.9–2.83)
  1. NA not applicable
  2. aRisk ratios values have been approximated using logistic regression analysis